Business Daily.
.
A+ R A-

imageCARLSBAD, Calif., Sept. 21, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced data from a Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.  FCS is a rare orphan disease characterized by severely......


Page 1546 of 1908

Grow Your Business with Times Media
Business Daily Media